Janux Therapeutics Inc (JANX)

Apr 5, 2025, 8:14 AM EDT - 17 days ago

Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout

Feb 27, 2025, 4:01 PM EST - 7 weeks ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Jan 24, 2025, 4:01 PM EST - 3 months ago

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Jan 8, 2025, 9:00 AM EST - 3 months ago

Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data

Jan 2, 2025, 11:46 PM EST - 3 months ago

Best-Performing Stocks Of 2024

APP BYRN CADL DAVE INOD LUNR MSTR

Dec 6, 2024, 7:43 PM EST - 4 months ago

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

Dec 4, 2024, 11:12 PM EST - 4 months ago

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Dec 3, 2024, 4:01 PM EST - 5 months ago

Janux Therapeutics Announces Proposed Public Offering

Dec 3, 2024, 10:49 AM EST - 5 months ago

Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst

Dec 3, 2024, 10:39 AM EST - 5 months ago

Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results

Dec 2, 2024, 4:30 PM EST - 5 months ago

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Nov 25, 2024, 9:00 AM EST - 5 months ago

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Nov 19, 2024, 1:23 AM EST - 5 months ago

Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation

Nov 6, 2024, 4:01 PM EST - 5 months ago

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Aug 7, 2024, 4:01 PM EDT - 9 months ago

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Jul 22, 2024, 4:01 PM EDT - 9 months ago

Janux Therapeutics Announces Updates to Board of Directors

Jun 26, 2024, 8:32 AM EDT - 10 months ago

Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy

May 7, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Apr 30, 2024, 12:06 AM EDT - 1 year ago

Janux Therapeutics (JANX) stock has gone parabolic: what next?

Apr 11, 2024, 9:00 AM EDT - 1 year ago

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 2, 2024, 2:10 AM EDT - 1 year ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT VKTX AMLX MCRB RAPT RVNC

Mar 20, 2024, 1:44 PM EDT - 1 year ago

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)

Mar 8, 2024, 4:01 PM EST - 1 year ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Feb 29, 2024, 1:22 AM EST - 1 year ago

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Feb 27, 2024, 5:15 PM EST - 1 year ago

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Feb 27, 2024, 5:00 PM EST - 1 year ago

Janux Therapeutics Announces Proposed Public Offering of Common Stock

Feb 27, 2024, 8:38 AM EST - 1 year ago

Janux Therapeutics surges as trial data for prostate cancer therapy shows promise

Feb 26, 2024, 4:05 PM EST - 1 year ago

Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors

Feb 20, 2024, 8:00 AM EST - 1 year ago

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008

Jan 8, 2024, 9:00 AM EST - 1 year ago

Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer

Nov 7, 2023, 4:01 PM EST - 1 year ago

Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Aug 8, 2023, 4:01 PM EDT - 1 year ago

Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Jul 17, 2023, 8:45 AM EDT - 1 year ago

Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Jul 17, 2023, 8:00 AM EDT - 1 year ago

Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

Jun 5, 2023, 4:35 PM EDT - 2 years ago

Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development

May 9, 2023, 4:01 PM EDT - 2 years ago

Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Apr 24, 2023, 4:01 PM EDT - 2 years ago

Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences

Apr 20, 2023, 4:01 PM EDT - 2 years ago

Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors

Mar 10, 2023, 4:01 PM EST - 2 years ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Feb 14, 2023, 12:00 PM EST - 2 years ago

Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference

Dec 27, 2022, 9:00 AM EST - 2 years ago

Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors

Nov 22, 2022, 6:00 AM EST - 2 years ago

Janux Therapeutics to Present at Upcoming Investor Conferences in November

Nov 10, 2022, 4:01 PM EST - 2 years ago

Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Oct 12, 2022, 9:00 AM EDT - 2 years ago

Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer

Sep 23, 2022, 6:00 AM EDT - 2 years ago

Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources

Sep 22, 2022, 6:00 AM EDT - 2 years ago

Janux Therapeutics Appoints Winston Kung to Board of Directors

Aug 31, 2022, 9:00 AM EDT - 2 years ago

Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September

Aug 9, 2022, 4:01 PM EDT - 2 years ago

Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

Jun 2, 2022, 8:00 AM EDT - 3 years ago

Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference

May 31, 2022, 8:00 AM EDT - 3 years ago

Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer